.svg)
The pharmaceutical industry is moving beyond broad population-based therapies toward increasingly targeted treatment strategies. Advances in genomics, biomarker-driven drug development, and precision diagnostics are enabling therapies designed for narrower patient groups with more defined clinical profiles. This shift is making personalised medicine a growing priority across pharmaceutical R&D and commercialisation.
However, developing a targeted therapy is only part of the equation. A medicine designed for a specific patient population still requires a delivery platform that can support dose flexibility, treatment adherence, and administration preferences. As therapies become more individualised, drug delivery systems are evolving from formulation considerations to strategic enablers of precision therapeutics.
This transition is accelerating demand for patient-centric drug delivery platforms that can accommodate greater therapeutic complexity while maintaining manufacturing scalability and regulatory consistency.
Traditional pharmaceutical manufacturing has largely been built around fixed-dose products intended for large patient populations. While this model has enabled efficient global production, it offers limited flexibility when treatment requirements vary significantly between patients.
In many therapeutic areas, dose optimisation depends on factors such as:
These variables are becoming increasingly relevant as personalised medicine expands across oncology, neurology, rare diseases, pediatrics, and chronic care.
Conventional tablets and capsules remain highly effective dosage forms, but they are inherently designed around fixed strengths and standardised administration pathways. As therapies become more individualised, pharmaceutical companies are increasingly evaluating whether existing dosage formats can keep up. The concern is added complexity in prescribing, manufacturing, or patient administration.
This is driving renewed interest in drug delivery systems that can offer greater flexibility while maintaining quality, scalability, and regulatory compliance.
One of the central goals of personalised medicine is delivering the right therapy at the right dose for the right patient.
Flexible drug delivery systems can support this objective by enabling:
Technologies such as multiparticulate systems, mini-tablets, advanced oral films, and digitally assisted dispensing platforms are creating new opportunities for individualised dosing while maintaining formulation precision.
For pharmaceutical companies, adherence remains a major determinant of real-world treatment success.
Complex dosing regimens, swallowing difficulties, and inconvenient administration methods can reduce long-term compliance, particularly in chronic therapies.
Patient-centric drug delivery addresses these barriers by focusing on:
As home-based care and self-administration continue to grow, these factors are becoming increasingly important in pharmaceutical product design.
The success of personalised medicine depends not only on identifying the appropriate therapy but also on ensuring that the therapy can be delivered effectively and consistently.
Advanced drug delivery systems can contribute to improved outcomes by supporting:
These capabilities are becoming increasingly relevant for complex therapies where therapeutic precision is critical.
Among emerging drug delivery systems, oral thin films are gaining significant attention for their ability to support the objectives of patient-centric drug delivery and personalised medicine.
Unlike conventional solid dosage forms, oral thin films dissolve rapidly in the oral cavity and do not require water for administration. This creates a more convenient treatment experience while supporting patients who may have difficulty swallowing tablets or capsules.
Several characteristics make oral thin films particularly attractive for individualised therapies:
These features can improve both patient acceptance and treatment adherence while supporting differentiated product strategies.
Oral thin films are especially relevant for patient populations where conventional oral dosage forms create adherence challenges.
For pediatric patients, they can support precise weight-based dosing and improve acceptance through taste masking. For geriatric and dysphagic patients, oral thin films eliminate the need to swallow large tablets and simplify administration.
Oral thin films combine precise drug loading with a flexible dosage architecture. Their thin-film design allows pharmaceutical developers to explore dose titration strategies more effectively, making them particularly relevant for therapies where dosing may need to be adjusted based on patient response, disease progression, or treatment tolerability.
Rapid dissolution further supports a more seamless patient experience. Rather than requiring patients to swallow tablets or capsules. The dosage form integrates more naturally into daily routines, helping reduce treatment burden while improving acceptability across diverse patient populations.
As discussed in our article, An Overview of CDMO Capabilities and Opportunities in Oral Thin Film Manufacturing, continued advances in film formulation, drug loading technologies, and manufacturing precision are expanding the role of oral thin films across a growing range of therapeutic applications.
The rise of personalised medicine is influencing both product development and manufacturing strategies across the pharmaceutical industry.
Pharmaceutical companies are increasing investment in technologies that support individualised treatment approaches, including oral thin films, modified-release formulations, multiparticulate systems, and other advanced drug delivery systems.
Traditional large-batch manufacturing models are increasingly being complemented by more flexible production approaches capable of supporting complex formulations and differentiated therapies.
Manufacturers are investing in modular facilities, advanced process controls, digital quality systems, and scalable small-batch capabilities to support the future of patient-centric drug delivery.
As delivery technologies become more sophisticated, pharmaceutical companies are increasingly partnering with specialised CDMOs that can provide expertise across formulation development, process optimisation, scale-up, regulatory support, and commercial manufacturing.
These partnerships help accelerate development timelines while reducing infrastructure investment requirements.
The growth of personalised medicine is creating new expectations for pharmaceutical product development. As therapies become more targeted, drug delivery platforms must evolve to accommodate greater dosing flexibility, improved patient usability, and increasingly diverse treatment requirements.
This is one reason why pharmaceutical companies are investing more heavily in advanced drug delivery systems rather than focusing solely on API innovation. The ability to tailor how a therapy is administered is just as important as the therapy itself, particularly in therapeutic areas where adherence, dosing precision, and patient experience directly influence treatment outcomes.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
